3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
13
Gynecologic
3
Breast
2
Head & Neck
1
Genitourinary
1
CNS
1
Conditions
Carcinoma, Renal Cell
37
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasm Metastasis
4
Kidney Neoplasms
4
Carcinoma, Transitional Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Clear-cell metastatic renal cell carcinoma
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Interventions
pembrolizumab
35
Nivolumab
14
Docetaxel
11
atezolizumab
10
Paclitaxel
9
Carboplatin
7
Gemcitabine
6
Cisplatin
6
Trastuzumab
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
Cyclophosphamide
5
Bevacizumab
5
fludarabine
4
avelumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Oxaliplatin
4
Leucovorin
4
Fluorouracil
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
cemiplimab
3
Taxes
3
Polymerase Chain Reaction
3
Pemetrexed
3
Irinotecan
3
Gene Expression Profiling
3
Early Intervention, Educational
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
lenvatinib
×
Genitourinary
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled